The neoadjuvant AG regimen resulted in a significant reduction in PDPN+ CAF contents and a decrease in extravasated platelet activation through PDPN+ CAF depletion, thereby preventing aggressive tumor cells from spreading, invading, and developing resistance to drugs (33). The gene discussed is PDPN; the disease is neoplasm.